Former Bristol-Myers Squibb svp/strategy Andrew Bodnar faces a year in prison after he pled guilty to lying to the FTC about BMS's generic deal with Apotex. The conviction carries a lesson for senior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback